Table 1 Baseline characteristics of participants according to the progression of glucose metabolism disturbance.
Progressors n = 72 | Non-progressors n = 182 | p | |
|---|---|---|---|
Women | 44 (61) | 104 (57) | 0.56 |
Age ≥ 60 years | 42 (58) | 84 (46) | 0.08 |
Increased BMI | 36 (50) | 104 (57.1) | 0.28 |
Abdominal obesity | 45 (62.5) | 104 (57.1) | 0.46 |
Hypertension | 31 (43) | 77 (43.1) | 0.91 |
Glucose metabolism | |||
Normal | 47 (65.3) | 41 (22.5) | <0.001 |
IFG or IGT | 25 (34.7) | 141 (77.5) | |
Dyslipidemia | 55 (76.4) | 151 (83.0) | 0.42 |
Insulin (uIU/mL) | |||
< 2.3 | 23 (41.1) | 51 (30.0) | 0.22 |
≥ 2.3 to < 4.8 | 23 (41.1) | 73 (42.9) | |
≥ 4.8 | 10 (17.9) | 46 (27.1) | |
Adiponectin (ng/mL) | |||
< 5.3 | 20 (33.2) | 58 (33.9) | 0.40 |
≥ 5.3 to < 8.8 | 17 (28.3) | 62 (36.3) | |
≥ 8.8 | 23 (38.3) | 51 (29.8) | |
C-reactive protein (mg/dL) | |||
< 0.04 | 11 (18.6) | 49 (28.7) | 0.02 |
≥ 0.04 to < 0.14 | 18 (30.5) | 70 (40.9) | |
≥ 0.14 | 30 (50.8) | 52 (30.4) | |
Interleukin-6 (pg/dL) | |||
< 1.8 | 14 (25.0) | 51 (30.2) | 0.76 |
≥ 1.8 to < 2.8 | 21 (37.5) | 58 (34.3) | |
≥ 2.8 | 21 (37.5) | 60 (35.5) | |
Tumor necrosis factor-α (pg/dL) | |||
< 3.6 | 18 (32.1) | 53 (31.4) | 0.98 |
≥ 3.6 to < 6.2 | 20 (35.7) | 59 (34.9) | |
≥ 6.2 | 18 (32.1) | 57 (33.7) |